Calcium/calmodulin-dependent protein kinase IIδ (CaMKIIδ) is an important regulator of cardiac contractile function and dysfunction and may be an unwanted secondary target for anti-cancer drugs such as sunitinib and imatinib that have been reported to alter cardiac performance. This study aimed to determine whether anti-cancer kinase inhibitors may affect CaMKII activity and expression when administered in vivo.
- cardiac contractility
- calcium/calmodulin-dependent protein kinase II
FingerprintDive into the research topics of 'Effect of acute and chronic sunitinib treatment on cardiac function and CaMKII'. Together they form a unique fingerprint.